Clinical outcomes and safety of continuous immunotherapy beyond progression in patients with extensive-stage small cell lung cancer: a retrospective real-world study

Key Points

• Prolonged second-line progression free survival is associated with continuous immunotherapy beyond progression in extensive-stage small cell lung cancer.
• The overall survival does not improve despite prolonged progression free survival, indicating a limitation of this approach.
• Retrospective real-world analysis reveals that chemotherapy is still a critical element of second-line treatment strategies.
• Anti-angiogenic agents may offer potential improvements, underlining the need for varied treatment approaches and further investigation.